1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,001 | 0,023 | 15:30 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.01. | Moss Genomics Inc.: Moss Genomics Reports Bitcoin Cash (BCH) Mining Activity | 292 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - January 5, 2026) - Moss Genomics Inc. (CSE: MOSS) (FSE: F73) (OTCQB: MSSGF) (the "Company" or "Moss") has announced it has mined a block on the Bitcoin... ► Artikel lesen | |
| MOSS GENOMICS Aktie jetzt für 0€ handeln | |||||
| 13.11.25 | Moss Genomics Inc: Moss Genomics closes $100,000 private placement | 3 | Stockwatch | ||
| 13.11.25 | Moss Genomics Inc.: Moss Genomics Announces Closing of Financing Round | 592 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - November 12, 2025) - Moss Genomics Inc. (CSE: MOSS) (FSE: F73) (OTCQB: MSSGF) (the "Company" or "Moss") announces that, effective as of November 11, 2025... ► Artikel lesen | |
| 11.07.25 | Moss Genomics Inc.: Moss Genomics Advances Blockchain Integration Strategy | 2.053 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - July 10, 2025) - Moss Genomics Inc. (CSE: MOSS) (FSE: F73) (OTCQB: MSSGF) (the "Company" or "Moss") is providing an update on its Ethereum (ETH) Treasury... ► Artikel lesen | |
| 19.06.25 | Moss Genomics Inc.: Moss Genomics Announces Strategic Investment in Genomes.io | 503 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - June 19, 2025) - Moss Genomics Inc. (CSE: MOSS) (FSE: F73) (OTCQB: MSSGF) (the "Company" or "Moss") is pleased to announce that on June 18, 2025, it has... ► Artikel lesen | |
| 28.04.25 | Moss Genomics Inc.: Moss Genomics Launches "Perennial" Genomics Platform, Closes on 130 ETH | 668 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - April 28, 2025) - Moss Genomics Inc. (CSE: MOSS) (FSE: F73) (OTCQB: MSSGF) (the "Company" or "Moss") is pleased to announce the public launch of its genomics... ► Artikel lesen | |
| 11.04.25 | Moss Genomics Inc.: Moss Genomics Announces Listing on the OTC Markets | 594 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - April 11, 2025) - Moss Genomics Inc. (CSE: MOSS) (OTCQB: MSSGF) (FSE: F73) (the "Company" or "Moss") is pleased to announce that its common shares are... ► Artikel lesen | |
| 26.02.25 | Moss Genomics Inc. Announces Leadership Changes | 286 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - February 26, 2025) - Moss Genomics Inc. (CSE: MOSS) (FSE: F73) ("Moss" or the "Company") is pleased to announce the appointment of Joseph De Pinto to... ► Artikel lesen | |
| 25.02.25 | Moss Genomics Inc.: Moss Genomics Announces Genomics Business Update, Integrating Blockchain for Genomic Security and Transparency | 306 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - February 25, 2025) - Moss Genomics Inc. (CSE: MOSS) (FSE: F73) (the "Company" or "Moss Genomics") is pleased to provide an update on its business strategy... ► Artikel lesen | |
| 04.02.25 | Moss Genomics Inc.: Moss Genomics Announces Private Placement and Agreement to Acquire Ethereum | 658 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - February 3, 2025) - Moss Genomics Inc. (CSE: MOSS) (FSE: F73) (the "Company" or "Moss") is pleased to announce a non-brokered private placement of up... ► Artikel lesen | |
| 01.02.25 | Moss Genomics Inc.: Moss Genomics Announces Closing of Private Placement, Acquisition of 160 Ethereum Cryptocurrency (ETH) and Welcomes Hunter Jordan to Its Board of Directors | 1.502 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - January 31, 2025) - Moss Genomics Inc. (CSE: MOSS) (FSE: F73) (the "Company" or "Moss") is pleased to announce that is has closed its previously announced... ► Artikel lesen |
11 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 44,715 | -1,69 % | Aktien Frankfurt Ausblick: Kleines Minus im Dax erwartet - Qiagen weiter stark | FRANKFURT (dpa-AFX) - Der deutsche Aktienmarkt bleibt auch am Mittwoch im Korrekturmodus. Nachdem sich zuletzt die Unsicherheit wegen der Zoll-Politik von US-Präsident Donald Trump wieder verstärkt... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 315,10 | +0,11 % | Piper Sandler raises Praxis Precision Medicines stock price target to $1,200 | ||
| BIONTECH | 97,25 | -2,02 % | BioNTech Aktie: Goldman Sachs mit Ritterschlag! Hohes Kurspotential! | © Foto: Foto von Ricardo Cruz auf UnsplashTolle News für die Mainzer. Goldman Sachs stuft BioNTech höher ein und setzt ein neues Kursziel. Das ist mehr als nur eine technische Anpassung. Es ist ein... ► Artikel lesen | |
| EVOTEC | 6,418 | +4,05 % | Evotec, A.H.T. Syngas Technology, Deutsche Telekom: Drei Aktien vor dem entscheidenden Wendepunkt? | Deutschlands Wirtschaft steht am Scheideweg. Die alten Stärken bröckeln, doch genau das eröffnet Chancen für Unternehmen, die sich strategisch neu ausrichten. Nicht einfache Anpassung, sondern ein fundamentaler... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,59 | -0,07 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| BEAM THERAPEUTICS | 29,040 | -5,41 % | Bernstein raises Beam Therapeutics stock price target to $41 on FDA pathway | ||
| STRUCTURE THERAPEUTICS | 89,57 | +0,07 % | Weight Loss Drugs Market Is Crowded But Structure Therapeutics CEO Has A Strategy For It | ||
| RECURSION PHARMACEUTICALS | 4,505 | -2,07 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen | |
| COGENT BIOSCIENCES | 38,170 | -0,86 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST) | - Cogent will submit the PEAK New Drug Application (NDA) under previously announced RTOR designation; on track to complete NDA submission in April 2026 WALTHAM, Mass. and BOULDER, Colo., Jan. 26... ► Artikel lesen | |
| CALCIMEDICA | 1,200 | -76,33 % | CalciMedica, Inc.: CalciMedica Announces Discontinuation of Phase 2 KOURAGE Trial in AKI Following Independent Data Monitoring Committee Recommendation | Safety concern warrants reevaluation of study design, including enrollment criteria
Potential future trial with Auxora in AKI to be evaluated after data analysis
... ► Artikel lesen | |
| ERASCA | 10,120 | -3,62 % | Erasca, Inc.: Erasca Announces Pricing of Upsized Public Offering of Common Stock | SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 15,550 | -2,14 % | Encouraging Guidance on Clinical Program Makes Summit Therapeutics (SMMT) Look Attractive | ||
| DISC MEDICINE | 80,86 | -1,56 % | Disc Medicine Inc: Disc Medicine Appoints Lisa Amaya Price, MBA as Chief Human Resources Officer | WATERTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 71,36 | -1,09 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs | KT-621 BROADEN2 Phase 2b trial in AD ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma initiated, with data expected in late-2027 KT-579 Phase 1 HV clinical trial expected... ► Artikel lesen | |
| NUVALENT | 101,98 | -4,20 % | Royalty Pharma plc: Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million | NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a pre-existing royalty interest in Nuvalent's neladalkib and zidesamtinib from an... ► Artikel lesen |
MOSS GENOMICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,026 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MOSS GENOMICS INC finden Sie auf Wallstreet Online.